GO
Loading...

Eli Lilly and Co

More

  • Final Glance: Pharmaceuticals companies Monday, 15 Sep 2014 | 6:03 PM ET

    Baxter International Inc. fell$. 15 or. 2 percent, to $74.55. Bristol-Myers Squibb Co. fell$. 31 or. 6 percent, to $49.95. Hospira rose$. 16 or. 3 percent, to $52.79.

  • Midday Glance: Pharmaceuticals companies Monday, 15 Sep 2014 | 1:24 PM ET

    Baxter International Inc. fell$. 31 or. 4 percent, to $74.39. Bristol-Myers Squibb Co. fell$. 32 or. 6 percent, to $49.95. Hospira rose$. 18 or. 3 percent, to $52.81.

  • Early Glance: Pharmaceuticals companies Monday, 15 Sep 2014 | 10:37 AM ET

    Baxter International Inc. fell$. 40 or. 5 percent, to $74.30. Bristol-Myers Squibb Co. fell$. 27 or. 5 percent, to $49.99. Johnson& Johnson fell$. 05 or percent, to $104.53.

  • Final Glance: Pharmaceuticals companies Friday, 12 Sep 2014 | 6:02 PM ET

    Baxter International Inc. fell$. 39 or. 5 percent, to $74.70. Bristol-Myers Squibb Co. fell$. 42 or. 8 percent, to $50.26. Hospira fell$. 36 or. 7 percent, to $52.63.

  • Midday Glance: Pharmaceuticals companies Friday, 12 Sep 2014 | 1:19 PM ET

    Baxter International Inc. fell$. 43 or. 6 percent, to $74.66. Bristol-Myers Squibb Co. fell$. 40 or. 8 percent, to $50.28. Hospira fell$. 35 or. 7 percent, to $52.64.

  • Early Glance: Pharmaceuticals companies Friday, 12 Sep 2014 | 11:13 AM ET

    Baxter International Inc. fell$. 26 or. 3 percent, to $74.83. Bristol-Myers Squibb Co. fell$. 12 or. 2 percent, to $50.56. Hospira fell$. 07 or. 1 percent, to $52.92.

  • Sept 12- Eli Lilly and Co's Cyramza stomach-cancer drug prolonged survival of patients with advanced colon cancer in a late-stage study, the U.S. drugmaker said on Friday. The 1,000- patient global study, called RAISE, involved patients who had previously failed to adequately benefit from Roche Holding AG's Avastin and other standard treatments.

  • Lilly cancer drug fares well in late-stage study Friday, 12 Sep 2014 | 10:38 AM ET

    INDIANAPOLIS— Eli Lilly and Co. said Friday its potential colorectal cancer drug Cyramza helped patients on chemotherapy with advanced cases of the disease survive longer than patients on chemotherapy alone.

  • Midday Glance: Pharmaceuticals companies Thursday, 11 Sep 2014 | 2:09 PM ET

    Baxter International Inc. fell$. 19 or. 2 percent, to $75.10. Bristol-Myers Squibb Co. fell$. 42 or. 8 percent, to $50.66. Hospira fell$. 16 or. 3 percent, to $53.00.

  • Early Glance: Pharmaceuticals companies Thursday, 11 Sep 2014 | 10:29 AM ET

    Baxter International Inc. fell$. 28 or. 4 percent, to $75.00. Bristol-Myers Squibb Co. fell$. 26 or. 5 percent, to $50.82. Hospira fell$. 03 or. 1 percent, to $53.12.

  • Final Glance: Pharmaceuticals companies Wednesday, 10 Sep 2014 | 6:16 PM ET

    Baxter International Inc. rose $1.01 or 1.4 percent, to $75.28. Bristol-Myers Squibb Co. rose$. 60 or 1.2 percent, to $51.08. Hospira rose$. 14 or. 3 percent, to $53.15.

  • Midday Glance: Pharmaceuticals companies Wednesday, 10 Sep 2014 | 1:21 PM ET

    Baxter International Inc. rose$. 84 or 1.1 percent, to $75.11. Bristol-Myers Squibb Co. rose$. 70 or 1.4 percent, to $51.18. Johnson& Johnson rose $1.10 or 1.1 percent, to $104.90.

  • Early Glance: Pharmaceuticals companies Wednesday, 10 Sep 2014 | 10:32 AM ET

    Baxter International Inc. rose$. 44 or. 6 percent, to $74.71. Bristol-Myers Squibb Co. rose$. 27 or. 5 percent, to $50.75. Johnson& Johnson rose$. 41 or. 4 percent, to $104.21.

  • Lilly receives European marketing OK for insulin Wednesday, 10 Sep 2014 | 10:13 AM ET

    INDIANAPOLIS— European regulators have approved a long-lasting insulin from Eli Lilly and Co. and German drugmaker Boehringer Ingelheim that is the subject of patent infringement litigation with French rival Sanofi. That is subject to a stay of more than two years due to the Sanofi litigation.

  • Sept 10- Eli Lilly and Co and Boehringer Ingelheim said on Wednesday that the European Commission approved their copycat version of Sanofi SA's blockbuster insulin, Lantus. The therapy received a positive recommendation from the European Medicine Agency in June.

  • Final Glance: Pharmaceuticals companies Tuesday, 9 Sep 2014 | 8:15 PM ET

    Baxter International Inc. rose$. 05 or. 1 percent, to $74.27. Bristol-Myers Squibb Co. fell$. 71 or 1.4 percent, to $50.48. Hospira rose$. 29 or. 6 percent, to $53.01.

  • Midday Glance: Pharmaceuticals companies Tuesday, 9 Sep 2014 | 1:22 PM ET

    Baxter International Inc. rose$. 12 or. 2 percent, to $74.34. Bristol-Myers Squibb Co. fell$. 46 or. 9 percent, to $50.73. Hospira rose$. 29 or. 6 percent, to $53.01.

  • Early Glance: Pharmaceuticals companies Tuesday, 9 Sep 2014 | 10:26 AM ET

    Baxter International Inc. rose$. 04 or. 1 percent, to $74.26. Bristol-Myers Squibb Co. fell$. 47 or. 9 percent, to $50.72. Hospira rose$. 01 or percent, to $52.73.

  • Final Glance: Pharmaceuticals companies Monday, 8 Sep 2014 | 6:38 PM ET

    Baxter International Inc. rose$. 02 or percent, to $74.22. Bristol-Myers Squibb Co. rose$. 07 or. 1 percent, to $51.19. Hospira fell $1.18 or 2.2 percent, to $52.72.

  • Midday Glance: Pharmaceuticals companies Monday, 8 Sep 2014 | 1:36 PM ET

    Baxter International Inc. rose$. 40 or. 5 percent, to $74.60. Bristol-Myers Squibb Co. fell$. 01 or percent, to $51.11. Hospira fell$. 88 or 1.6 percent, to $53.02.